Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Budesonide (Rhinocort; Budicort; Entocort; Rhinosol; Pulmicort; Symbicort; Noex Entocort EC) is a synthetic glucocorticoid steroid approved for use in the treatment of inflammatory conditions such as asthma, non-infectious rhinitis, and nasal polyposis. In addition, it is used for treating Crohn's disease (inflammatory bowel disease).
ln Vitro |
In CV-1 cells, budesonide preferentially binds to the human glucocorticoid receptor (hGR; EC50=45.7 pM) as opposed to the mineralocorticoid receptor (EC50=7,620 pM). In macrophages (RAW 264.7 cells), budesonide (30 min before LPS) inhibits the activation of the NLRP3 inflammasome by LPS (100 ng/mL) + ATP (5 mM)[2].
|
---|---|
ln Vivo |
Lung tumor size is reduced by budesonide (2.0 mg/kg; orally via diet; at 2, 7 and 21 days prior to killing)[3]. Pretreatment with budesonide (0.5 mg/kg; intranasal given 1 hour before to LPS injection (5 mg/kg)) significantly attenuates pathological harm and lowers pathological scores in adult male C57BL/6 mice with ALI[2].
|
Animal Protocol |
Animal/Disease Models: Female strain A/J mice at 8 weeks of age[3]
Doses: 2.0 mg/ kg Route of Administration: Orally via their diet; at 2, 7 and 21 days prior to killing (27 weeks) Experimental Results: decreased the size of the lung tumors after 2 days and rapidly diminished the size of lung tumors, reversed DNA hypomethylation and modulated mRNA expression of genes. |
References |
[1]. Claudia Grossmann, et al. Transactivation via the Human Glucocorticoid and Mineralocorticoid Receptor by Therapeutically Used Steroids in CV-1 Cells: A Comparison of Their Glucocorticoid and Mineralocorticoid Properties. Eur J Endocrinol. 2004 Sep;151(3):
[2]. Liang Dong, et al. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice. J Imm [3]. Michael A Pereira, et al. Modulation by Budesonide of DNA Methylation and mRNA Expression in Mouse Lung Tumors. Int J Cancer. 2007 Mar 1;120(5):1150-3. |
Molecular Formula |
C25H34O6
|
|
---|---|---|
Molecular Weight |
430.53
|
|
CAS # |
51333-22-3
|
|
Related CAS # |
Budesonide-d8;1105542-94-6;Budesonide (Standard);51333-22-3
|
|
SMILES |
O1[C@]([H])(C([H])([H])C([H])([H])C([H])([H])[H])O[C@]2([H])C([H])([H])[C@@]3([H])[C@]4([H])C([H])([H])C([H])([H])C5=C([H])C(C([H])=C([H])[C@]5(C([H])([H])[H])[C@@]4([H])[C@]([H])(C([H])([H])[C@]3(C([H])([H])[H])[C@]12C(C([H])([H])O[H])=O)O[H])=O
|
|
InChi Key |
VOVIALXJUBGFJZ-KWVAZRHASA-N
|
|
InChi Code |
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
|
|
Chemical Name |
(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2,1:4,5] indeno[1,2-d][1,3]dioxol-4(2H)-one
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3227 mL | 11.6136 mL | 23.2272 mL | |
5 mM | 0.4645 mL | 2.3227 mL | 4.6454 mL | |
10 mM | 0.2323 mL | 1.1614 mL | 2.3227 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.